E-Newsletter - December 2023
In Memoriam | Worta J. McCaskill-Stevens, MD
Founding Director, NCI Community Oncology Research Program (NCORP)
Worta J. McCaskill-Stevens, MD, former chief of the National Cancer Institute’s (NCI) Community Oncology and Prevention Trials Research Group and former director of the NCI Community Oncology Research Program (NCORP), died November 15, 2023. She was 74.
Dr. McCaskill-Stevens was a nationally known physician-scientist with expertise in leading clinical trials in the community. She worked as a breast cancer oncologist before joining NCI in 1998 in the Community Clinical Oncology Program. She served as program director for the Study of Tamoxifen and Raloxifene (STAR), one of the largest breast cancer prevention studies ever undertaken. In the trial, conducted at 500 centers in the United States, Canada and Puerto Rico, both drugs greatly reduced the risk of developing invasive breast cancer in women at high risk. She also co-led the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), an ongoing, international breast cancer screening trial of nearly 130,000 women ages 45 to 74. She "walked the talk" and participated in TMIST, as well.
Dr. McCaskill-Stevens has made a tremendous impact on cancer health disparities research both nationally and internationally, and in management of comorbidities within clinical trials, and molecular research that helps to identify those individuals who will best benefit from cancer prevention interventions. Her passion and curiosity for breast cancer led her to really focus on research related to the cancer and the multiple factors involved in improving access and health outcomes for this population. She retired on October 31 after 25 years of service in the NCI. Her passion, leadership and vision made the NCORP and the Alliance the powerful and impactful force it is today in driving cancer prevention, control and treatment research into all communities, especially diverse communities, to make an impact on cancer outcomes.
She is noted saying, “You must have curiosity about your interest which often develops into a passion and commitment to pursue the topic in depth. Follow this path and seek out others who have travelled it." She certainly lived up to these high expectations until the very end and is a real inspiration to all of us who strive towards making the lives of patients with cancer better.
During the 2023 Alliance Fall Hybrid Group Meeting in November, the Alliance Cancer Control Program renamed its annual health disparities symposium - "The Worta McCaskill-Stevens, MD, MS Health Disparities Symposium" in honor of Dr. McCaskill-Stevens' leadership and work with the NCI NCORP.
Read other articles in this month's e-newsletter:
- Message From the Group Chair
- New Alliance Leadership Appointments
- 2023 Richard L. Schilsky CALGB Achievement Award
- Recently Activated Alliance Trials
- Ongoing Alliance Trials Now Enrolling Participants
- 2022-2023 Most Notable Alliance Publications
- Spotlight on Scientific Annual Meetings: 2023 SABCS & ASH
- In Memoriam: Worta J. McCaskill-Stevens, MD, MS - Founding Director, NCI Community Oncology Research Program (NCORP)
- Alliance Foundation Special Allocation Funding Opportunity
- Alliance/Alliance Entities Holiday Closures
-
Alliance in the News
:: Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
:: Can Irinotecan Boost Complete Response Rate and Long-term Organ Preservation in Rectal Cancer Patients?
:: Sex-Associated Differences in Frequencies and Prognostic Impact of Recurrent Genetic Alterations in Adult Acute Myeloid Leukemia (Alliance, AMLCG)
:: DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations
:: ctDNA May Guide Treatment Intensity in RCC
:: Quality of Life, Access Top Priorities in Cancer Care
:: Dual-action Drug Produces Shows Promising Results In Neuroendocrine Tumor Trial
:: Alliance for Clinical Trials in Oncology Study Shows Promise for Patients with Muscle-Invasive Urothelial Carcinoma
:: Clinical Trial Shows Promising Results for Patients with Advanced Neuroendocrine Tumors
:: Older, Hispanic Patients More Likely to Withdraw From Cancer Trials